Esperion Theraptc Cmn (ESPR) 10.78 $ESPR Is Esp
Post# of 273258
Posted On: 09/03/2016 1:09:31 AM
Esperion Theraptc Cmn (ESPR) 10.78 $ESPR
Is Esperion Therapeutics (ESPR) Stock a Solid Choice Right Now?
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 7:36AM CDT
One stock that might be an intriguing choice for investors right now is Esperion Therapeutics, Inc.(ESPR)
ESPR: 10.78 (+0.02)
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:13PM CDT
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today provided bempedoic acid (ETC-1002) development program updates and financial results for the second quarter ended June 30, 2016.
ESPR: 10.78 (+0.02)
Looking Into Biotech's Crystal Ball
ACCESSWIRE - Thu May 19, 3:35PM CDT
LAS VEGAS, NV / ACCESSWIRE / May 19, 2016 / While biotech investing is riddled with risk it is also ripe with reward. One way we can mitigate risk in this rough and tumble sector that has made millionaires of many and bankrupted some is to pay attention to subtext and follow the company's true progress. Especially when dealing with development stage biotechs.
ESPR: 10.78 (+0.02)
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 7:05AM CDT
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C, today provided bempedoic acid (ETC-1002) development program updates and financial results for the first quarter ended March 31, 2016.
ESPR: 10.78 (+0.02)
Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 10.78 (+0.02), CMRX: 4.62 (unch), GERN: 2.75 (+0.02), CYTX: 2.05 (unch), CLDX: 3.35 (-0.01), SGMO: 4.32 (-0.01), PTCT: 7.91 (+0.12), ATHX: 1.91 (-0.03), MNKD: 0.74 (unch)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Esperion Therapeutics, Inc. and a Lead Plaintiff Deadline of March 14, 2016
BusinessWire - Wed Feb 10, 1:14PM CST
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of Michigan on behalf of investors who purchased Esperion Therapeutics, Inc. (NASDAQ: ESPR) securities between August 18, 2015 and September 28, 2015.
ESPR: 10.78 (+0.02)
ESPERION INVESTORS ALERT: Lieff Cabraser Reminds Investors of Deadline in Class Action Against Esperion Therapeutics, Inc.
BusinessWire - Tue Feb 09, 4:09PM CST
The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in securities class litigation brought on behalf of investors who purchased the common stock of Esperion Therapeutics, Inc. ("Esperion" or the "Company"
(NASDAQ:ESPR) between August 18, 2015 and September 28, 2015, inclusive (the "Class Period" .
ESPR: 10.78 (+0.02)
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Esperion Therapeutics, Inc. To Contact The Firm Before Upcoming Lead Plaintiff Deadline
PR Newswire - Tue Feb 09, 11:43AM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Esperion Therapeutics, Inc. ("Esperion" or the "Company" (NasdaqGM:ESPR) of the March 14, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
ESPR: 10.78 (+0.02)
Global Obesity Pipeline Review, H2 2015 - Therapeutics Under Development by Leading Companies and Universities
M2 - Tue Feb 09, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/4fs2cn/obesity) has announced the addition of the "Obesity - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesityand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - ObesityOverview - Therapeutics Development - Pipeline Products for Obesity - Overview - Pipeline Products for Obesity - Comparative Analysis - Obesity - Therapeutics under Development by Companies - Obesity - Therapeutics under Investigation by Universities/Institutes - Obesity - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Obesity - Products under Development by Companies - Obesity - Products under Investigation by Universities/Institutes - Obesity - Companies Involved in Therapeutics Development Companies Mentioned - Sample List of the 35 Companies Featured - Abeome Corporation - Advinus Therapeutics Ltd. - Aegis Therapeutics, LLC - Akron Molecules AG - Alize Pharma SAS - Amabiotics SAS - Ambrx, Inc. - Amgen Inc. - Arena Pharmaceuticals, Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca Plc - Asubio Pharma Co., Ltd. - AtheroNova Inc. - Avaxia Biologics, Inc. - BioLingus AG - BioRestorative Therapies, Inc. - BioTime, Inc. - Boehringer Ingelheim GmbH - Braasch Biotech LLC - Bristol-Myers Squibb Company - Camurus AB - Carmot Therapeutics, Inc. - Chronos Therapeutics Limited - CohBar, Inc. - CoMentis, Inc. - Daiichi Sankyo Company, Limited - Deltanoid Pharmaceuticals Inc. - Diabetica Limited - DiscoveryBiomed, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Esperion Therapeutics, Inc. - Euroscreen S.A. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. For more information visit http://www.researchandmarkets.com/research/4fs2cn/obesity
AMBX: (), AMGN: 169.77 (-0.36), LLY: 76.85 (-0.38), BMY: 56.35 (-0.41), ESPR: 10.78 (+0.02), AZN: 33.31 (+0.71), FGEN: 17.84 (+0.51), ARNA: 1.57 (+0.01)
INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Esperion Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
BusinessWire - Mon Feb 08, 11:09AM CST
Lundin Law PC announces a class action lawsuit has been filed against Esperion Therapeutics, Inc. ("Esperion" or the "Company" (NASDAQ: ESPR) concerning possible violations of federal securities laws between August 18, 2015 and September 28, 2015. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the March 14, 2016, lead plaintiff motion deadline.
ESPR: 10.78 (+0.02)
INVESTOR ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Involving Esperion Therapeutics, Inc. and a Lead Plaintiff Deadline of March 14, 2016 - ESPR
GlobeNewswire - Fri Feb 05, 1:15PM CST
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of Michigan on behalf of investors who purchased Esperion Therapeutics, Inc. (NASDAQ:ESPR) securities between August 18, 2015 and September 28, 2015.
ESPR: 10.78 (+0.02)
Hagens Berman Reminds Esperion Therapeutics, Inc. (NASDAQGM: ESPR) Investors of March 14, 2016 Lead Plaintiff Deadline
GlobeNewswire - Thu Feb 04, 10:03AM CST
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, alerts Esperion Therapeutics, Inc. (NASDAQ:ESPR) investors there is a March 14, 2016 lead plaintiff deadline in the securities fraud class action lawsuit filed against the Company related to the delayed approval of Esperion's leading cholesterol drug.
ESPR: 10.78 (+0.02)
SHAREHOLDER ALERT: Lundin Law PC Announces an Ongoing Investigation of Esperion Therapeutics, Inc. and Urges Investors With Losses in Excess of $500,000 to Contact the Firm
BusinessWire - Wed Feb 03, 12:53PM CST
Lundin Law PC announces it is investigating claims against Esperion Therapeutics, Inc. ("Esperion" or the "Company" (Nasdaq: ESPR) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Esperion were false and misleading and/or failed to disclose material information regarding the Company's financial performance.
ESPR: 10.78 (+0.02)
GPM Commences Investigation on Behalf of Esperion Therapeutics, Inc. Investors
BusinessWire - Wed Feb 03, 9:30AM CST
Glancy Prongay & Murray LLP ("GPM" announces that it is investigating potential claims on behalf of investors of Esperion Therapeutics, Inc. ("Esperion" or the "Company" (NASDAQ: ESPR) concerning the Company and its officers' possible violations of federal securities laws.
ESPR: 10.78 (+0.02)
Investor Alert: Peiffer Rosca Wolf Law Firm announces filing of a shareholder class action against Esperion Therapeutics, Inc. ("Esperion" or "Company" (NASDAQ: ESPR) in the U.S. District Court for the Eastern District of Michigan.
PR Newswire - Tue Feb 02, 10:25AM CST
To obtain more information about this lawsuit, Esperion investors are encouraged to contact Alan Rosca or James Booker toll free at 888-998-0520 or by email at arosca@prwlegal.com or by filling out the contact form on our website, www.esperionclassaction.com.
ESPR: 10.78 (+0.02)
KILL Investor Alert: Peiffer Rosca Wolf Law Firm Announces Filing of a Shareholder Class Action against Esperion Therapeutics, Inc. ("Esperion" or "Company" (NASDAQ: ESPR) in the U.S. District Court for the Eastern District of Michigan
BusinessWire - Mon Feb 01, 7:34PM CST
Peiffer Rosca Wolf Abdullah Carr & Kane requests that their press release NewsItemId: 20160201006413 entitled "Investor Alert: Peiffer Rosca Wolf Law Firm Announces Filing of a Shareholder Class Action against Esperion Therapeutics, Inc. ("Esperion" or "Company" (NASDAQ: ESPR) in the U.S. District Court for the Eastern District of Michigan" be killed.
ESPR: 10.78 (+0.02)
Investor Alert: Peiffer Rosca Wolf Law Firm Announces Filing of a Shareholder Class Action against Esperion Therapeutics, Inc. ("Esperion" or "Company" (NASDAQ: ESPR) in the U.S. District Court for the Eastern District of Michigan
BusinessWire - Mon Feb 01, 5:11PM CST
To obtain more information about this lawsuit, Esperion investors are encouraged to contact Alan Rosca or James Booker toll free at 888-998-0520 or by email at arosca@prwlegal.com, or by filling out the contact form on our website, www.esperionclassaction.com.
ESPR: 10.78 (+0.02)
ESPR INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Esperion Therapeutics, Inc.
BusinessWire - Mon Feb 01, 4:13PM CST
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been brought on behalf of purchasers of the common stock of Esperion Therapeutics, Inc. ("Esperion" or the "Company" (Nasdaq: ESPR) between August 18, 2015 and September 28, 2015, inclusive (the "Class Period" .
ESPR: 10.78 (+0.02)
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Esperion Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of March 14, 2016 - ESPR
GlobeNewswire - Mon Feb 01, 10:47AM CST
The following statement is being issued by Levi & Korsinsky, LLP:
ESPR: 10.78 (+0.02)
The Former Attorney General of Louisiana & Kahn Swick & Foti, LLC Remind Large Investors of Lead Plaintiff Deadline in Class Action Lawsuit Against Esperion Therapeutics, Inc. - ESPR
GlobeNewswire - Fri Jan 29, 9:00PM CST
Kahn Swick & Foti, LLC ("KSF" and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2016 to file lead plaintiff applications in a securities class action lawsuit against Esperion Therapeutics, Inc. (Nasdaq:ESPR), if they purchased the Company's securities between August 18, 2015 through September 28, 2015, inclusive (the "Class Period" . This action is pending in the United States District Court for the Eastern District of Michigan.
ESPR: 10.78 (+0.02)
Is Esperion Therapeutics (ESPR) Stock a Solid Choice Right Now?
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 7:36AM CDT
One stock that might be an intriguing choice for investors right now is Esperion Therapeutics, Inc.(ESPR)
ESPR: 10.78 (+0.02)
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:13PM CDT
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today provided bempedoic acid (ETC-1002) development program updates and financial results for the second quarter ended June 30, 2016.
ESPR: 10.78 (+0.02)
Looking Into Biotech's Crystal Ball
ACCESSWIRE - Thu May 19, 3:35PM CDT
LAS VEGAS, NV / ACCESSWIRE / May 19, 2016 / While biotech investing is riddled with risk it is also ripe with reward. One way we can mitigate risk in this rough and tumble sector that has made millionaires of many and bankrupted some is to pay attention to subtext and follow the company's true progress. Especially when dealing with development stage biotechs.
ESPR: 10.78 (+0.02)
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 7:05AM CDT
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C, today provided bempedoic acid (ETC-1002) development program updates and financial results for the first quarter ended March 31, 2016.
ESPR: 10.78 (+0.02)
Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 10.78 (+0.02), CMRX: 4.62 (unch), GERN: 2.75 (+0.02), CYTX: 2.05 (unch), CLDX: 3.35 (-0.01), SGMO: 4.32 (-0.01), PTCT: 7.91 (+0.12), ATHX: 1.91 (-0.03), MNKD: 0.74 (unch)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Esperion Therapeutics, Inc. and a Lead Plaintiff Deadline of March 14, 2016
BusinessWire - Wed Feb 10, 1:14PM CST
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of Michigan on behalf of investors who purchased Esperion Therapeutics, Inc. (NASDAQ: ESPR) securities between August 18, 2015 and September 28, 2015.
ESPR: 10.78 (+0.02)
ESPERION INVESTORS ALERT: Lieff Cabraser Reminds Investors of Deadline in Class Action Against Esperion Therapeutics, Inc.
BusinessWire - Tue Feb 09, 4:09PM CST
The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in securities class litigation brought on behalf of investors who purchased the common stock of Esperion Therapeutics, Inc. ("Esperion" or the "Company"
(NASDAQ:ESPR) between August 18, 2015 and September 28, 2015, inclusive (the "Class Period" . ESPR: 10.78 (+0.02)
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Esperion Therapeutics, Inc. To Contact The Firm Before Upcoming Lead Plaintiff Deadline
PR Newswire - Tue Feb 09, 11:43AM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Esperion Therapeutics, Inc. ("Esperion" or the "Company"
(NasdaqGM:ESPR) of the March 14, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers. ESPR: 10.78 (+0.02)
Global Obesity Pipeline Review, H2 2015 - Therapeutics Under Development by Leading Companies and Universities
M2 - Tue Feb 09, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/4fs2cn/obesity) has announced the addition of the "Obesity - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesityand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - ObesityOverview - Therapeutics Development - Pipeline Products for Obesity - Overview - Pipeline Products for Obesity - Comparative Analysis - Obesity - Therapeutics under Development by Companies - Obesity - Therapeutics under Investigation by Universities/Institutes - Obesity - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Obesity - Products under Development by Companies - Obesity - Products under Investigation by Universities/Institutes - Obesity - Companies Involved in Therapeutics Development Companies Mentioned - Sample List of the 35 Companies Featured - Abeome Corporation - Advinus Therapeutics Ltd. - Aegis Therapeutics, LLC - Akron Molecules AG - Alize Pharma SAS - Amabiotics SAS - Ambrx, Inc. - Amgen Inc. - Arena Pharmaceuticals, Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca Plc - Asubio Pharma Co., Ltd. - AtheroNova Inc. - Avaxia Biologics, Inc. - BioLingus AG - BioRestorative Therapies, Inc. - BioTime, Inc. - Boehringer Ingelheim GmbH - Braasch Biotech LLC - Bristol-Myers Squibb Company - Camurus AB - Carmot Therapeutics, Inc. - Chronos Therapeutics Limited - CohBar, Inc. - CoMentis, Inc. - Daiichi Sankyo Company, Limited - Deltanoid Pharmaceuticals Inc. - Diabetica Limited - DiscoveryBiomed, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Esperion Therapeutics, Inc. - Euroscreen S.A. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. For more information visit http://www.researchandmarkets.com/research/4fs2cn/obesity
AMBX: (), AMGN: 169.77 (-0.36), LLY: 76.85 (-0.38), BMY: 56.35 (-0.41), ESPR: 10.78 (+0.02), AZN: 33.31 (+0.71), FGEN: 17.84 (+0.51), ARNA: 1.57 (+0.01)
INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Esperion Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
BusinessWire - Mon Feb 08, 11:09AM CST
Lundin Law PC announces a class action lawsuit has been filed against Esperion Therapeutics, Inc. ("Esperion" or the "Company"
(NASDAQ: ESPR) concerning possible violations of federal securities laws between August 18, 2015 and September 28, 2015. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the March 14, 2016, lead plaintiff motion deadline. ESPR: 10.78 (+0.02)
INVESTOR ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Involving Esperion Therapeutics, Inc. and a Lead Plaintiff Deadline of March 14, 2016 - ESPR
GlobeNewswire - Fri Feb 05, 1:15PM CST
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of Michigan on behalf of investors who purchased Esperion Therapeutics, Inc. (NASDAQ:ESPR) securities between August 18, 2015 and September 28, 2015.
ESPR: 10.78 (+0.02)
Hagens Berman Reminds Esperion Therapeutics, Inc. (NASDAQGM: ESPR) Investors of March 14, 2016 Lead Plaintiff Deadline
GlobeNewswire - Thu Feb 04, 10:03AM CST
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, alerts Esperion Therapeutics, Inc. (NASDAQ:ESPR) investors there is a March 14, 2016 lead plaintiff deadline in the securities fraud class action lawsuit filed against the Company related to the delayed approval of Esperion's leading cholesterol drug.
ESPR: 10.78 (+0.02)
SHAREHOLDER ALERT: Lundin Law PC Announces an Ongoing Investigation of Esperion Therapeutics, Inc. and Urges Investors With Losses in Excess of $500,000 to Contact the Firm
BusinessWire - Wed Feb 03, 12:53PM CST
Lundin Law PC announces it is investigating claims against Esperion Therapeutics, Inc. ("Esperion" or the "Company"
(Nasdaq: ESPR) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Esperion were false and misleading and/or failed to disclose material information regarding the Company's financial performance. ESPR: 10.78 (+0.02)
GPM Commences Investigation on Behalf of Esperion Therapeutics, Inc. Investors
BusinessWire - Wed Feb 03, 9:30AM CST
Glancy Prongay & Murray LLP ("GPM"
announces that it is investigating potential claims on behalf of investors of Esperion Therapeutics, Inc. ("Esperion" or the "Company" (NASDAQ: ESPR) concerning the Company and its officers' possible violations of federal securities laws. ESPR: 10.78 (+0.02)
Investor Alert: Peiffer Rosca Wolf Law Firm announces filing of a shareholder class action against Esperion Therapeutics, Inc. ("Esperion" or "Company"
(NASDAQ: ESPR) in the U.S. District Court for the Eastern District of Michigan. PR Newswire - Tue Feb 02, 10:25AM CST
To obtain more information about this lawsuit, Esperion investors are encouraged to contact Alan Rosca or James Booker toll free at 888-998-0520 or by email at arosca@prwlegal.com or by filling out the contact form on our website, www.esperionclassaction.com.
ESPR: 10.78 (+0.02)
KILL Investor Alert: Peiffer Rosca Wolf Law Firm Announces Filing of a Shareholder Class Action against Esperion Therapeutics, Inc. ("Esperion" or "Company"
(NASDAQ: ESPR) in the U.S. District Court for the Eastern District of Michigan BusinessWire - Mon Feb 01, 7:34PM CST
Peiffer Rosca Wolf Abdullah Carr & Kane requests that their press release NewsItemId: 20160201006413 entitled "Investor Alert: Peiffer Rosca Wolf Law Firm Announces Filing of a Shareholder Class Action against Esperion Therapeutics, Inc. ("Esperion" or "Company"
(NASDAQ: ESPR) in the U.S. District Court for the Eastern District of Michigan" be killed. ESPR: 10.78 (+0.02)
Investor Alert: Peiffer Rosca Wolf Law Firm Announces Filing of a Shareholder Class Action against Esperion Therapeutics, Inc. ("Esperion" or "Company"
(NASDAQ: ESPR) in the U.S. District Court for the Eastern District of Michigan BusinessWire - Mon Feb 01, 5:11PM CST
To obtain more information about this lawsuit, Esperion investors are encouraged to contact Alan Rosca or James Booker toll free at 888-998-0520 or by email at arosca@prwlegal.com, or by filling out the contact form on our website, www.esperionclassaction.com.
ESPR: 10.78 (+0.02)
ESPR INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Esperion Therapeutics, Inc.
BusinessWire - Mon Feb 01, 4:13PM CST
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been brought on behalf of purchasers of the common stock of Esperion Therapeutics, Inc. ("Esperion" or the "Company"
(Nasdaq: ESPR) between August 18, 2015 and September 28, 2015, inclusive (the "Class Period" . ESPR: 10.78 (+0.02)
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Esperion Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of March 14, 2016 - ESPR
GlobeNewswire - Mon Feb 01, 10:47AM CST
The following statement is being issued by Levi & Korsinsky, LLP:
ESPR: 10.78 (+0.02)
The Former Attorney General of Louisiana & Kahn Swick & Foti, LLC Remind Large Investors of Lead Plaintiff Deadline in Class Action Lawsuit Against Esperion Therapeutics, Inc. - ESPR
GlobeNewswire - Fri Jan 29, 9:00PM CST
Kahn Swick & Foti, LLC ("KSF"
and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2016 to file lead plaintiff applications in a securities class action lawsuit against Esperion Therapeutics, Inc. (Nasdaq:ESPR), if they purchased the Company's securities between August 18, 2015 through September 28, 2015, inclusive (the "Class Period" . This action is pending in the United States District Court for the Eastern District of Michigan. ESPR: 10.78 (+0.02)
(0)
(0)Scroll down for more posts ▼